Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+ in patients with grass pollen-induced allergic rhinoconjunctivitis during two successive pollen seasons

Next Previous
Trial Profile

A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+ in patients with grass pollen-induced allergic rhinoconjunctivitis during two successive pollen seasons

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABT 011 (Primary)
  • Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Sponsors DMS Imaging

Most Recent Events

  • 09 Oct 2020 Status changed from active, no longer recruiting to discontinued.
  • 09 Oct 2020 This trial has been discontinued in Poland, according to European Clinical Trials Database record.
  • 22 Jul 2020 This trial has been discontinued in Czech Republic, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top